CILO CYBIN HOLDINGS LIMITED - Appointment of Chief Commercial Officer and Executive Director

Appointment of Chief Commercial Officer and Executive Director

Cilo Cybin Holdings Limited
Incorporated in the Republic of South Africa
(Registration number 2022/320351/06)
Share code: CCC ISIN: ZAE000310397
Listed on the General Segment of the JSE
Issuer with a weighted voting structure
(“Cilo Cybin” or “the Company” or “the Group”)


APPOINTMENT OF GROUP CHIEF COMMERCIAL OFFICER AND EXECUTIVE DIRECTOR


In compliance with paragraph 6.71 of the Listings Requirements of the JSE Limited, the board of directors of Cilo
Cybin (“the Board”) notifies shareholders that Mr Ian McFarlane has been appointed as Group Chief Commercial
Officer and an executive director of the Company with effect from 20 October 2026.

Mr McFarlane joins from IPS Pharma, where, as Director of Strategic Partnerships, he played a central role in
building one of the UK’s leading importers and distributors of medicinal cannabis products, with partners across
Europe, North America, Australasia, South America and Africa. He managed the importation and partner
management for the PANORAMIC, PRINCIPLE and RECOVERY clinical trials, run with the University of Oxford.
PANORAMIC and RECOVERY have been described by the University of Oxford and UK Research and
Innovation (UKRI) as among the largest trials of their kind in the world.

He has over 30 years of experience in the pharmaceutical industry, including senior commercial roles at Sanofi,
Zentiva and Merck Generics, and has launched more than 200 branded and generic pharmaceutical products.
In his new role, Mr McFarlane will lead the Group’s international trade and commercial relationships beyond
South Africa.

Gabriel Theron, Chief Executive Officer, said: “We are pleased that Ian has chosen to join us. His international
experience and commercial relationships will support the Group’s development as we extend our reach beyond
South Africa.”

The Board confirms that it has undertaken a fit and proper assessment of Mr McFarlane and is satisfied with the
outcome. The Company confirms that there are no positive statements in respect of the integrity information
contained in Mr McFarlane’s director’s declaration.
The Board welcomes Mr McFarlane and looks forward to his contribution to the Group.


Johannesburg
21 October 2026

Sponsor
Merchantec Capital
Date: 21/10/2026 03:28:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.